NCT06430645 Effects of Esketamine on Recovery of Consciousness After Propofol Anesthesia
| NCT ID | NCT06430645 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tiantan Hospital |
| Condition | Post-anesthesia Recovery |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-05-05 |
| Primary Completion | 2024-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2024-05-05 with a primary completion date of 2024-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Esketamine is an antagonist of N-methyl-d-aspartate (NMDA) receptor different from other gamma-aminobutyric acid (GABA) receptor agonists. Recent studies showed that subanesthetic doses of ketamine not only deepen anesthesia but also accelerate recovery from isoflurane anesthesia in mice. It is necessary to verify if it applies to human. Besides inducing behavioral unresponsiveness, an optimal and important goal of general anesthesia is to prevent connected consciousness. The results of many studies support the conclusion that anesthesia-related unconsciousness is a consistent functional disconnection of lateral frontoparietal networks.The goal of this clinical trial is to learn if subanaesthetic doses of esketamine works to accelerate the recovery of consciousness from propofol anesthesia. It will also learn about the change of brain network when administrated the esketamine during propofol anesthesia. The main questions it aims to answer are: 1. Does subanaesthetic doses of esketamine can accelerate recovery from propofol anaesthesia? 2. What will happen to brain network connection after different doses of esketamine during propofol anesthesia?
Eligibility Criteria
Inclusion Criteria: * Aged from 18 years to 50 years * Patients scheduled for elective operative hysteroscopy * Willing to sign informed consent Exclusion Criteria: * Contraindications of propofol and esketamine * Contraindications for EEG; * ASA≥III; * BMI≥30 kg/m2 or BMI\<18 kg/m2; * The MMSE scale score is lower than the normal value; * Alcohol or drug abuse; * Untreated or under-treated hypertension, hyperthyroidism, risk of increased intracranial pressure, audio-visual impairment, history of psychiatric disorders or neurological diseases, malignant tumors or other major diseases; * Use of other neurological drugs or drugs known to interact with propofol and esketamine in the past 2 weeks; * Pregnant and lactating women; * The operation duration is shorter than 15 minutes or longer than 60 minutes.
Contact & Investigator
Ruquan Han, PhD
PRINCIPAL INVESTIGATOR
Beijing Tiantan Hospital
Frequently Asked Questions
Who can join the NCT06430645 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying Post-anesthesia Recovery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06430645 currently recruiting?
Yes, NCT06430645 is actively recruiting participants. Contact the research team at liyang0519@mail.ccmu.edu.cn for enrollment information.
Where is the NCT06430645 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06430645 clinical trial?
NCT06430645 is sponsored by Beijing Tiantan Hospital. The principal investigator is Ruquan Han, PhD at Beijing Tiantan Hospital. The trial plans to enroll 150 participants.